Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$24.99
-$0.47(-5.84%)
At close: 4:00 PM EST
$24.99
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$3.20 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.13M
Market Cap
$3.38B
Enterprise Value$2.82B
Total Cash (Recent Filing)$522.94M
Total Debt (Recent Filing)$35.66M
Price to Earnings (P/E)―
Beta-1.39
Next Earnings
Aug 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding123,432,076
10 Day Avg. Volume1,545,199
30 Day Avg. Volume1,133,995
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue335.26
Enterprise Value/Gross Profit374.04
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$39.43Price Target Upside57.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$7.82M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity provides durable financial flexibility: it reduces near-term refinancing risk and gives management runway to fund R&D or strategic initiatives without immediate reliance on costly borrowing, cushioning the company while clinical programs advance.
High Gross Margins / Unit EconomicsSustainably high gross margins indicate favorable unit economics for eventual product commercialization: if clinical programs succeed, product sales could scale with attractive incremental margins, helping long-term profitability once fixed R&D costs normalize post-launch.
Validated TYK2 Strategy And Broad PipelineClinical validation (Phase 3 psoriasis success) and a strategy targeting a multibillion-dollar immunology market provide structural upside: a differentiated TYK2 approach, multiple indications and near-term readouts create durable optionality and multiple paths to commercial scale if regulatory success follows.
Bears Say
Severe Cash BurnVery high operating cash outflows create persistent funding risk: ongoing trials and development will likely require external capital, increasing dilution or strategic dependency. Heavy burn constrains optionality and can force trade-offs across programs if financing conditions tighten.
Sharp Revenue DeclineA steep drop in revenue weakens non-dilutive funding and suggests limited commercial or partner-derived cash inflows; for a development-stage biotech this elevates reliance on capital markets and increases execution risk, making sustained program funding more uncertain.
Large Operating Losses / Negative ReturnsOngoing sizable operating losses have produced strongly negative returns on equity, risking equity erosion over time: absent successful clinical outcomes or new capital, persistent losses will degrade shareholder value and may necessitate dilutive financings or program cuts.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $3.20 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.38B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 42 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on May 14, 2026. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.003.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.72.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,432,076 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -7.146%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.43 (57.78% Upside)
$39.43 (57.78% Upside)
Hedge Fund Trend
Increased
By 294.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 20.2%
Last 30 Days ▲ 20.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
707.92%
12-Months-Change
Fundamentals
Return on Equity
-54.63%
Trailing 12-Months
Asset Growth
157.02%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$39.43
▲(57.78% Upside)
Technical Analysis
Ownership Overview
56.33% Insiders
5.30% Mutual Funds
3.31% Other Institutional Investors
26.92% Public Companies and
Individual Investors